Invisible Illness: Leading the Way on Long COVID
https://m.youtube.com/live/-eorSN8x498?si=OOoUXh9fHb1LwFbC

Dr. Bruce Patterson, IncellDx spoke at this U.S. Department of Health and Human Services roundtable with other COVID long hauler researchers. View him from 1:38-1:44 about his success with differentiating long #covid from #Lyme patients and novel treatment.

My inquiry to Dr. Patterson: (His reply follows)

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: brucep@incelldx.com
Cc: ASH@hhs.gov
Date: 09/20/2025 10:17 AM EDT
Subject: Invisible Illness: Leading the Way on Long COVID
 
Long COVID diagnostic with differentiation from chronic lyme disease using machine learning and cytokine hubs
https://pmc.ncbi.nlm.nih.gov/articles/PMC11347643/
 
Discussion
 
"Targeting individual cytokines underlying the immunopathogenesis of these conditions may provide a powerful new tool in the treatment of these immunologically mediated disorders using precision medicine. Further study may elucidate how pathogen or antigen persistence or reactivation could contribute to these classifications."
 
 
 
Bruce K Patterson MD
IncellDx Inc,
30920 Huntwood Ave,
San Carlos, Hayward, CA 94544 USA
 
Dear Dr Patterson,
 
Thank you for your work on Long COVID and chronic Lyme disease.
 
Questions:
 
1. In the study above, is it possible that your observations/findings in the chronic Lyme cohort are markers for persistent infection? I do not see where you ruled out active disease.
2. Are the novel treatments you mention in your interview; Invisible Illness: Leading the Way on Long COVID treating persistent Borrelia infection? (Maraviroc/atorvastatin)

 
Please see the following comment and peer reviewed research by Dr. Ying Zhang which was coauthored by past IDSA president Paul G Auwaerter.
 
Auwaerter is the lead author of the deplorable Lacent paper: Lyme disease antiscience orchestrating a campaign to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients yet the research he coauthored below identifies the reason why Lyme disease persists after antibiotic treatment.
 
Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria.
http://droopyyoupi.blogspot.com/2015/08/standart-antibiotic-treatment-for-lyme.html
 
 
Excerpt:
 
-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
 
- Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
 
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
 
-Two days after NorVect conference, published Dr. Ying Zhang's latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
 
 
 
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
 
Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1
 
https://pubmed.ncbi.nlm.nih.gov/27242757/
 
Abstract
 
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline. 
 
 
 
Dr Patterson… A response to this inquiry is requested.
 
 
Respectfully Submitted,
 
 
Carl Tuttle
Independent Researcher
Hudson, NH

 
Response from Dr. Patterson:
 
---------- Original Message ----------
From: Bruce Patterson <brucep@incelldx.com>
To: CARL TUTTLE <runagain@comcast.net>
Cc: ASH@hhs.gov
Date: 09/20/2025 10:25 AM EDT
Subject: Re: Invisible Illness: Leading the Way on Long COVID
 
 
Our new publication will address all of this as we found fragments of Borrelia protein activating monocytes in the absence of replication and hence refractory to antibiotics. We are using drugs that induce apoptosis in this population to “empty the garbage can”